Phase 1 Evaluation of H1 Influenza Vaccine Delivered by MIMIX MAP - Trial NCT06125717
Access comprehensive clinical trial information for NCT06125717 through Pure Global AI's free database. This Phase 1 trial is sponsored by Vaxess Technologies and is currently Completed. The study focuses on Influenza. Target enrollment is 45 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Vaxess Technologies
Timeline & Enrollment
Phase 1
Jul 02, 2022
Mar 13, 2023
Primary Outcome
To determine the safety of VX-103 delivered as a single MIMIX MAP immunization
Summary
A Phase 1, Randomized, Rater and Participant Blinded Placebo Controlled Study to Evaluate the
 Safety, Reactogenicity, Tolerability and Immunogenicity of a Standard and a Fractional Dose
 of H1 Influenza Vaccine Delivered by VX-103 (a MIMIX Microneedle Array Patch (MAP) System) in
 Healthy Adults ≥18-39 Years of Age
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06125717
Non-Device Trial